Aligos Therapeutics announced that the company remains on track to complete all Phase 2-enabling activities in 2023 for ALG-055009, its thyroid hormone receptor beta drug candidate for nonalcoholic steatohepatitis, NASH. "Initial Phase 1 clinical data demonstrate that ALG-055009 is favorably differentiated compared to frontrunner THR-ss drug candidates such as resmetirom," said Lawrence Blatt, Ph.D., MBA, CEO and Chairman of the Board at Aligos. "The dose-proportional pharmacokinetics and low variability observed with ALG-055009 indicate that, compared to other THR-ss drugs, more predictable and consistent ALG-055009 exposures may be achieved across diverse patient populations. This, in turn, may result in more consistent, and potentially greater, pharmacodynamic effects. The planned upcoming Phase 2 study of ALG-055009 will be important in assessing the spectrum of activity of this molecule. We look forward to elaborating on this and the rest of our pipeline during our presentation at the upcoming JP Morgan conference in San Francisco."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALGS:
- Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
- Aligos Therapeutics initiates dosing in ALG-125755 trial
- Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)
- Aligos presents nonclinical data for coronavirus therapeutic program
